

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/935.061
		Filing Date	August 21, 2001
		First Named Inventor	KOBILKA, BRIAN K.
		Group Art Unit	1645 1646
		Examiner Name	To Be Assigned Rukiang
Sheet 1 of 2	Attorney Docket Number	STAN-213	

RECEIVED
APR 10 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		Bertin, et al. "Cellular Signaling by an Agonsit-activated receptor/Gsa Fusion Protein", <i>Proc. Natl. Acad. Sci. USA</i> , (1994) Vol. 91: 8827-8831.	
		Bond, et al. "Do Recent Operational Studies Indicate That a Single State Model Is No Longer Applicable to G Protein-Coupled Receptors?", <i>Annals of New York Acad Sci.</i> , (1997) Vol. 812: 92-97.	
		Chidiac, et al. "Agonist-induced modulation of Inverse Agonsit Efficacy at the β_2 -Adrenergic Receptor", <i>Molecular Pharmacology</i> , 50: 662-669 (1996).	
		Gether, et al. "Fluorescent Labeling of Purified β_2 Adrenergic Receptor", <i>Biochem.</i> , (1996) Vol. 35: 14040-14046. <i>Duplicate</i>	
		Gether, et al. "Agonists induce Conformational Changes in Transmembrane Domains III and VI of the β_2 Adrenoceptor", <i>The EMBO Journal</i> Vol. 16 No.22 pgs 6737-6747 (1994). <i>Duplicate</i>	
		Hopkinson, et al. "Non-Competitive Anatagonism of β_2 -Agonsit-Mediated Cyclic AMP Accumulation by ICI 118551 in BC3H1 Cells Endogenously Expressing Constitutively Active β_2 -Adrenoceptors", <i>British Journal of Pharmacology</i> , 131: 124-130 (2000).	
RLi		Peter Mombaerts "Seven-Transmembrane Proteins as Odorant abd Chemosensory Receptors", <i>Science</i> Vol. 286 (1999) pgs 707-711.	

Examiner Signature	<i>Rukiang L.</i>	Date Considered	4/4/2004
-----------------------	-------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08a (05-03)
Approved for use through 04/30/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Compl to if Known	
		Application Number	09/935,081
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	August 21, 2001
		First Named Inventor	KOBILKA, BRIAN K.
		Art Unit	1646
		Examiner Name	LI, RUIXIANG
		Attorney Docket Number	STAN-213
Sheet	1	of	1

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US			
		US			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RLi		BALLESTEROS et al. "Structural Mimicry in G Protein-Coupled Receptors: Implications of the High-Resolution Structure of Rhodopsin for Structure-Function Analysis of Rhodopsin-Like Receptors" <i>Molecular Pharmacology</i> Vol. 60, No. 1, pp. 1-19 2001	
		CERIONE et al. "Specificity of the Functional Interactions of the β -Adrenergic Receptor and Rhodopsin with Guanine Nucleotide Regulatory Proteins Reconstituted in Phospholipid Vesicles" <i>The Journal of Biological Chemistry</i> , Vol. 260., No. 3, 02/10/1985, pp. 1493-1500	
		FREDRIKSSON et al. "The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints" <i>Molecular Pharmacology</i> , Vol. 63., No. 6., 1256-1272 (2003)	
		MIRZADEGAN et al. "Sequence Analysis of G-Protein-Coupled Receptors: Similarities to Rhodopsin" <i>American Chemical Society</i> , Vol. 42., No. 10, March 18, 2003 pp. 2759-2767	
		OKADA et al. "Functional role of internal water molecules in rhodopsin revealed by x-ray crystallography" <i>PNAS</i> April 30, 2002., Vol. 99, No. 9 pp. 5982-5987	
RLi		WARD et al. "Conformational Changes That Occur during M ³ Muscarinic Acetylcholine Receptor Activation Probed by the Use of an In Situ Disulfide Cross-Linking Strategy" <i>The Journal of Biological Chemistry</i> , Vol. 277, No 3 01/18/2002, pp. 2247-2257	

Examiner Signature	RuiXiang Li	Date Considered	4/4/2004
-----------------------	-------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/935,061		
		Filing Date	August 21, 2001		
		First Named Inventor	KOBILKA, BRIAN K.		
		Group Art Unit	1645-1646		
		Examiner Name	To Be Assigned <i>Ruixiang Li</i>		
Sheet	2	of	2	Attorney Docket Number	STAN-213

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		Remmers, et al. "Partial G Protein Activation by Fluorescent Guanine Nucleotide Analogs", The Journal of Biological Chemistry, (1996) Vol. 271, No. 9: pgs 4791-4797.	
RLi		Seifert, et al. "Reconstitution of β_2 -Adrenoceptor-GTP-Binding-Protein Interaction in SF9 Cells High Coupling efficiency in a β_2 -Adrenoceptor-G _s Fusion Protein", Eur J. Biochem., 255: 369-382 (1998).	
RLi		Phillip G. Strange "Agonism and Inverse Agonism at Dopamine D ₂ -Like Receptors", Clinical and Experimental Pharm and Physio., 26 (Suppl) S3-S9 (1999).	

Examiner Signature	<i>Ruixiang Li</i>	Date Considered	4/4/2004
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.